A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 132, Issue 3, 2014, Pages 526-530

  Martin, Lainie P ^a   Sill, Michael ^b   Shahin, Mark S ^c   Powell, Matthew ^d   Disilvestro, Paul ^e   Landrum, Lisa M ^f   Gaillard, Stephanie L ^g   Goodheart, Michael J ^h   Hoffman, James ⁱ   Schilder, Russell J ^j  

^a FOX CHASE CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ABINGTON MEMORIAL HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BROWN UNIVERSITY   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

ⁱ NEW BRITAIN GENERAL HOSPITAL   (United States)

^j THOMAS JEFFERSON UNIVERSITY   (United States)

more..

Author keywords

AMG 102; Clinical trial; HGF; OVARIAN CANCER; Rilotumumab MET; Scatter factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; RILOTUMUMAB; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPONATREMIA; HYPOTENSION; LEUKOCYTE COUNT; METABOLIC DISORDER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTE COUNT; THROMBOEMBOLISM; UTERINE TUBE CARCINOMA; VERY ELDERLY;

AMG 102; CLINICAL TRIAL; HGF; OVARIAN CANCER; RILOTUMUMAB MET; SCATTER FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE;

EID: 84896390900     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.12.018     Document Type: Article

References (28)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. B. Peruzzi, and D.P. Bottaro Targeting the c-Met signaling pathway in cancer Clin Cancer Res 12 2006 3657 3660
3. M.F. Di Renzo, R.P. Narsimhan, M. Olivero, S. Bretti, S. Giordano, and E. Medico et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues Oncogene 6 1991 1997 2003
4. S. Benvenuti, and P.M. Comoglio The MET receptor tyrosine kinase in invasion and metastasis J Cell Physiol 213 2007 316 325
5. P.M. Comoglio Pathway specificity for Met signalling Nat Cell Biol 3 2001 E161 E162
6. F. Maina, G. Pante, F. Helmbacher, R. Andres, A. Porthin, and A.M. Davies et al. Coupling Met to specific pathways results in distinct developmental outcomes Mol Cell 7 2001 1293 1306
7. S. Rahman, Y. Patel, J. Murray, K.V. Patel, R. Sumathipala, and M. Sobel et al. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells BMC Cell Biol 6 1 2005 8
8. L. Trusolino, A. Bertotti, and P.M. Comoglio A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth Cell 107 2001 643 654
9. N. Ahmed, E.W. Thompson, and M.A. Quinn Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm J Cell Physiol 213 2007 581 588
10. L. Lamorte, I. Royal, M. Naujokas, and M. Park Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions Mol Biol Cell 13 2002 1449 1461
11. K.M. Weidner, J. Behrens, J. Vandekerckhove, and W. Birchmeier Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells J Cell Biol 111 1990 2097 2108
12. H.M. Sowter, A.N. Corps, and S.K. Smith Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells Int J Cancer 83 1999 476 480
13. Y. Ueoka, K. Kato, and N. Wake Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via Ras mediated pathway Mol Cell Endocrinol 202 2003 81 88
14. K.M. Weidner, M. Sachs, and W. Birchmeier The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells J Cell Biol 121 1993 145 154
15. M.F. Di Renzo, M. Olivero, D. Katsaros, T. Crepaldi, P. Gaglia, and P. Zola et al. Overexpression of the Met/HGF receptor in ovarian cancer Int J Cancer 58 1994 658 662
16. D. Huntsman, J.H. Resau, E. Klineberg, and N. Auersperg Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy Am J Pathol 155 1999 343 348
17. A.N. Corps, H.M. Sowter, and S.K. Smith Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met Int J Cancer 73 1997 151 155
18. A.S. Wong, P.C. Leung, and N. Auersperg Hepatocyte growth factor promotes in vitro scattering and morphogenesis of human cervical carcinoma cells Gynecol Oncol 78 2000 158 165
19. A.S. Wong, S.L. Pelech, M.M. Woo, G. Yim, B. Rosen, and T. Ehlen et al. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? Oncogene 20 2001 1318 1328
20. K. Sawada, A.R. Radjabi, N. Shinomiya, E. Kistner, H. Kenny, and A.R. Becker et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion Cancer Res 67 2007 1670 1679
21. C. To, and M. Tsao The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers Oncol Rep 5 1998 1013 1024
22. M.S. Gordon, C.S. Sweeney, D.S. Mendelson, S.G. Eckhardt, A. Anderson, and D.M. Beaupre et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors Clin Cancer Res 16 2010 699 710
23. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
24. M.W. Sill, L. Rubinstein, S. Litwin, and G. Yothers A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials Clin Trials 9 2012 385 395
25. L. Usha, M.W. Sill, K.M. Darcy, D.M. Benbrook, J.A. Hurteau, and D.P. Michelin et al. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies Gynecol Oncol 121 2011 455 461
26. P.Y. Wen, D. Schiff, T.F. Cloughesy, J.J. Raizer, J. Laterra, and M. Smitt et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma Neuro Oncol 13 2011 437 446
27. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, and J.O. Park et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
28. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481